{"id":"https://openalex.org/W4379980362","doi":"https://doi.org/10.1002/hon.3165_596","title":"RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA","display_name":"RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379980362","doi":"https://doi.org/10.1002/hon.3165_596","pmid":"https://pubmed.ncbi.nlm.nih.gov/39112272"},"language":"en","primary_location":{"id":"doi:10.1002/hon.3165_596","doi":"https://doi.org/10.1002/hon.3165_596","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3165_596","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_596","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_596","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. S. Davids","raw_affiliation_strings":["Dana-Farber Cancer Institute, Department of Oncology, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Department of Oncology, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030703994","display_name":"Joshua Ryan Richter","orcid":"https://orcid.org/0000-0002-0274-0585","observed_orcids":["https://orcid.org/0000-0002-0274-0585"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Richter","raw_affiliation_strings":["Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046328444","display_name":"Colin Anderson\u2010Smits","orcid":"https://orcid.org/0000-0002-2734-6154","observed_orcids":["https://orcid.org/0000-0002-2734-6154"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Anderson\u2010Smits","raw_affiliation_strings":["Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066006969","display_name":"Marta M. Kamieniak","orcid":"https://orcid.org/0009-0001-9931-2228","observed_orcids":["https://orcid.org/0009-0001-9931-2228"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Kamieniak","raw_affiliation_strings":["Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011596791","display_name":"Kunming Ren","orcid":"https://orcid.org/0009-0009-9966-7799","observed_orcids":["https://orcid.org/0009-0009-9966-7799"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Ren","raw_affiliation_strings":["Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087430965","display_name":"D. Shah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Shah","raw_affiliation_strings":["Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062219947","display_name":"Csaba Siffel","orcid":"https://orcid.org/0000-0002-6491-6953","observed_orcids":["https://orcid.org/0000-0002-6491-6953"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Siffel","raw_affiliation_strings":["Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4220,"currency":"USD","value_usd":4220},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.08764108,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"S2","first_page":"745","last_page":"746"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.015200000256299973,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9279999732971191},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/secondary-immunodeficiency","display_name":"secondary immunodeficiency","score":0.9359999895095825},{"id":"https://openalex.org/keywords/infection-burden","display_name":"infection burden","score":0.7760000228881836},{"id":"https://openalex.org/keywords/hypogammaglobulinemia","display_name":"hypogammaglobulinemia","score":0.9610000252723694},{"id":"https://openalex.org/keywords/recurrent-infections","display_name":"recurrent infections","score":0.7450000047683716},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7400000095367432},{"id":"https://openalex.org/keywords/infection-related-mortality","display_name":"infection-related mortality","score":0.45500001311302185},{"id":"https://openalex.org/keywords/lymphoid-malignancies","display_name":"lymphoid malignancies","score":0.4819999933242798},{"id":"https://openalex.org/keywords/immunodeficiency-screening","display_name":"immunodeficiency screening","score":0.38600000739097595},{"id":"https://openalex.org/keywords/immunoglobulin-replacement-therapy","display_name":"immunoglobulin replacement therapy","score":0.47999998927116394},{"id":"https://openalex.org/keywords/prophylaxis","display_name":"prophylaxis","score":0.39100000262260437},{"id":"https://openalex.org/keywords/immunosuppressive-therapy","display_name":"immunosuppressive therapy","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8736391067504883},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6922587156295776},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6212586164474487},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.6204603910446167},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.4453667402267456},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.420423686504364},{"id":"https://openalex.org/C2777607303","wikidata":"https://www.wikidata.org/wiki/Q641307","display_name":"Immunodeficiency","level":3,"score":0.4105093479156494},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3407225012779236},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.32606250047683716},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.17830073833465576},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D003226","descriptor_name":"Congresses as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D013557","descriptor_name":"Switzerland","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/hon.3165_596","doi":"https://doi.org/10.1002/hon.3165_596","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3165_596","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_596","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},{"id":"pmid:39112272","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39112272","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological oncology","raw_type":"Congress"}],"best_oa_location":{"id":"doi:10.1002/hon.3165_596","doi":"https://doi.org/10.1002/hon.3165_596","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3165_596","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_596","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320333965","display_name":"Takeda Pharmaceuticals International","ror":"https://ror.org/002ysmy84"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4379980362.pdf","grobid_xml":"https://content.openalex.org/works/W4379980362.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4385667393","https://openalex.org/W4402494393","https://openalex.org/W4283373583","https://openalex.org/W4394685093","https://openalex.org/W4385667047","https://openalex.org/W4405092866","https://openalex.org/W4399305498","https://openalex.org/W7117320285","https://openalex.org/W4295817047","https://openalex.org/W4319439202"],"abstract_inverted_index":{"Introduction:":[0],"Patients":[1,70,370],"with":[2,43,71,171,186,198,203,236,253,285,299,345,371],"lymphoid":[3],"malignancies":[4],"such":[5],"as":[6],"chronic":[7,434],"lymphocytic":[8,11,435],"leukaemia":[9],"(CLL)/small":[10],"lymphoma":[12,440],"(SLL)":[13],"are":[14],"at":[15,354],"risk":[16],"of":[17,39,49,87,92,111,121,128,146,175,234,267,283,297,314,381,392,395,442],"developing":[18],"secondary":[19],"immunodeficiency":[20],"disease":[21],"(SID),":[22],"which":[23],"can":[24],"lead":[25],"to":[26,29,142,399,408,445,470,479,493],"increased":[27],"susceptibility":[28],"severe,":[30],"recurrent":[31],"or":[32,126,452,515,545,559,573,587,601],"persistent":[33],"infections.":[34],"This":[35,52],"study":[36,56],"evaluated":[37],"burden":[38,380,394],"infection":[40,240,315,333,382,396],"in":[41,66,149,184,257,322,359,402],"patients":[42,133,166,185,197,235,284,298,324,344,384],"and":[44,75,109,155,179,188,201,204,295,342,346,472,487,496,509,533,540],"without":[45,76,134,205,243,347],"SID":[46,72,77,88,114,151,237,244,259,361,376],"following":[47],"diagnosis":[48,154,174],"CLL/SLL.":[50,176],"Methods:":[51],"observational,":[53],"retrospective":[54],"cohort":[55,260,362,367],"was":[57,117,139,262,316,334,357,413,423],"conducted":[58],"using":[59],"anonymized":[60],"data":[61],"from":[62],"the":[63,67,118,136,144,150,254,258,329,360,365,446],"Optum-Humedica":[64],"database":[65],"USA":[68],"(1-Oct-15\u201310-Mar-20).":[69],"(SID":[73,210,269],"cohort)":[74,79],"(no-SID":[78],"were":[80,158,167,182,208,350],"identified":[81,159],"1-Apr-16\u201310-Mar-19":[82],"(selection":[83],"window).":[84],"The":[85,113,310,411],"definition":[86],"included":[89,209],"International":[90,428],"Classification":[91],"Diseases,":[93],"Tenth":[94],"Revision,":[95],"Clinical":[96],"Modification":[97],"(ICD-10-CM)":[98],"hypogammaglobulinaemia":[99],"(HGG)":[100],"codes,":[101],"low":[102,129],"immunoglobulin":[103],"G":[104],"(IgG)":[105],"levels":[106],"(<5.0":[107],"g/L)":[108],"signs/symptoms":[110],"SID.":[112,389],"index":[115,137,147],"date":[116,138],"earliest":[119],"occurrence":[120],"an":[122,327],"ICD-10-CM":[123],"HGG":[124],"code":[125],"record":[127],"IgG":[130],"levels.":[131],"In":[132],"SID,":[135,206,348],"randomly":[140],"assigned":[141],"replicate":[143],"distribution":[145],"dates":[148],"cohort.":[152],"CLL/SLL":[153,372],"baseline":[156],"characteristics":[157],"during":[160],"a":[161,172,231,264,378],"6-month":[162],"pre-index":[163],"period.":[164],"Included":[165],"aged":[168],"\u226518":[169],"years":[170],"confirmed":[173],"Infection-related":[177],"outcomes":[178,401],"overall":[180,339],"survival":[181,353],"assessed":[183],"\u226512-month":[187],"\u22653":[189],"months":[190,356],"follow-up":[191],"post-index":[192],"date,":[193],"respectively.":[194],"Results:":[195],"Of":[196],"CLL/SLL,":[199],"502":[200],"3928":[202],"respectively,":[207,349],"vs":[211,225,270],"no-SID:":[212,247,271,290,305,320],"mean":[213,272],"[standard":[214],"deviation;":[215],"SD]":[216],"age":[217],"70.6":[218],"[9.7]":[219],"vs.":[220,276],"71.6":[221],"[10.5]":[222],"years;":[223],"59.2%":[224],"57.7%":[226],"male).":[227],"At":[228],"12-month":[229],"follow-up,":[230],"larger":[232],"proportion":[233,282,296],"had":[238,377],"\u22651":[239,286,300],"than":[241,364,383],"those":[242,323],"(SID:":[245,288,303,318],"70.1%;":[246],"30.4%;":[248],"p":[249,279,292,307],"<":[250,280,293,308],"0.001).":[251,309],"Compared":[252],"no-SID":[255,366],"cohort,":[256],"there":[261],"also":[263],"higher":[265],"number":[266],"infections":[268],"[SD]:":[273],"8.4":[274],"[12.7]":[275],"4.1":[277],"[5.4];":[278],"0.001),":[281],"SBI":[287],"39.8%;":[289],"9.2%;":[291],"0.001)":[294],"infection-associated":[301],"hospitalization":[302],"27.7%;":[304],"5.8%;":[306],"most":[311,330],"common":[312],"type":[313],"bacterial":[317,335],"63.7%;":[319],"24.9%);":[321],"who":[325,373,385],"experienced":[326],"SBI,":[328],"frequently":[331],"reported":[332],"pneumonia.":[336],"To":[337],"assess":[338],"survival,":[340],"646":[341],"4719":[343],"included.":[351],"Overall":[352],"24":[355],"lower":[358],"(77.3%)":[363],"(87.2%).":[368],"Conclusions:":[369],"subsequently":[374],"developed":[375],"greater":[379],"did":[386],"not":[387],"develop":[388],"Increasing":[390],"understanding":[391],"this":[393,403],"may":[397],"help":[398],"improve":[400],"population":[404],"Encore":[405],"Abstract\u2014previously":[406],"submitted":[407],"EHA":[409],"2023":[410],"research":[412],"funded":[414,424],"by:":[415,425],"Takeda":[416,426,473,532,548,555,562,569,576,583,590,597,604,611],"Development":[417,549,563,577,591,605],"Center":[418,550,564,578,592,606],"Americas,":[419,551,565,579,593,607],"Inc.":[420,552,566,580,594,608],"Writing":[421],"support":[422,477,491],"Pharmaceuticals":[427],"AG.":[429],"Keywords:":[430],"cancer":[431],"health":[432],"disparities,":[433],"leukemia":[436],"(CLL),":[437],"indolent":[438],"non-Hodgkin":[439],"Conflicts":[441],"interests":[443],"pertinent":[444],"abstract":[447],"M.":[448,556],"S.":[449],"Davids":[450],"Consultant":[451,514],"advisory":[453,516],"role":[454,517],"AbbVie,":[455],"Adaptive":[456,518],"Biotechnologies,":[457,519],"Aptitude":[458],"Health,":[459],"BeiGene,":[460],"Bioascend,":[461],"Celgene,":[462,524],"Curio":[463],"Science,":[464],"Eli":[465],"Lilly,":[466],"Janssen,":[467,525],"Merck,":[468],"Research":[469],"Practice":[471],"Other":[474],"remuneration:":[475],"Grant":[476],"(paid":[478,492],"his":[480,494],"institution):":[481],"Bristol":[482,502,521,537],"Myers":[483,503,522,538],"Squibb,":[484,504,523],"Secura":[485,530],"Bio":[486],"Surface":[488],"Oncology;":[489],"grant":[490],"institution)":[495],"consulting":[497],"fees:":[498],"Ascentage":[499],"Pharma,":[500,507],"AstraZeneca,":[501,520],"Genentech,":[505],"MEI":[506],"Pharmacyclics":[508],"TG":[510],"Therapeutics.":[511],"J.":[512],"Richter":[513],"Karyopharm":[526],"Therapeutics,":[527],"Oncopeptides,":[528],"Sanofi,":[529],"Bio,":[531],"X4":[534],"Pharmaceuticals.":[535],"Honoraria:":[536],"Squibb":[539],"Janssen":[541],"C.":[542,598],"Anderson-Smits":[543],"Employment":[544,558,572,586,600],"leadership":[546,560,574,588,602],"position:":[547,561,575,589,603],"Stock":[553,567,581,595,609],"ownership:":[554,568,582,596,610],"Kamieniak":[557],"K.":[570],"Ren":[571],"D.":[584],"Shah":[585],"Siffel":[599]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2023-06-10T00:00:00"}